ASO Author Reflections: Informing Patients About New Genetic Testing

  • Minerva A. Romero Arenas
  • Elizabeth G. GrubbsEmail author
ASO Author Reflections



The authors declare that they have no conflict of interest.


  1. 1.
    Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610CrossRefGoogle Scholar
  2. 2.
    Plouin PF, Amar L, Dekkers OM, et al. Guideline Working Group. European Society of Endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174(5):G1–10.CrossRefGoogle Scholar
  3. 3.
    Lenders JW, Duh QY, Eisenhofer G, et al. Endocrine Society. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42.CrossRefGoogle Scholar
  4. 4.
    NGS in PPGL (NGSnPPGL) Study Group, Toledo RA, Burnichon N, Cascon A, et al. Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol. 2017;13:233–47. Scholar
  5. 5.
    Arenas MAR, Rich TA, Hyde SM, et al. Recontacting patients with updated genetic testing recommendations for medullary thyroid carcinoma and pheochromocytoma or paraganglioma. Ann Surg Oncol. 2018;25(5):1395–402. (Epub 2018 Feb 9).CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Minerva A. Romero Arenas
    • 1
    • 2
  • Elizabeth G. Grubbs
    • 1
    Email author
  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of SurgeryThe University of Texas Rio Grande ValleyEdinburgUSA

Personalised recommendations